[1]刘素荣,权 阳,朱 娇,等.非小细胞肺癌组织中KPNB1，MERTK的表达水平与临床病理特征的相关性及无进展生存预后的研究[J].现代检验医学杂志,2025,40(01):53-58.[doi:10.3969/j.issn.1671-7414.2025.01.010]
　LIU Surong,QUAN Yang,ZHU Jiao,et al.Expression Levels of KPNB1 and MERTK in NSCLS Tissues and Correlation with the Clinical Pathological Features and the Prognosis of Progression Free Survival[J].Journal of Modern Laboratory Medicine,2025,40(01):53-58.[doi:10.3969/j.issn.1671-7414.2025.01.010]
点击复制

非小细胞肺癌组织中KPNB1，MERTK的表达水平与临床病理特征的相关性及无进展生存预后的研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
53-58
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Expression Levels of KPNB1 and MERTK in NSCLS Tissues and Correlation with the Clinical Pathological Features and the Prognosis of Progression Free Survival
文章编号:
1671-7414（2025）01-053-06
作者:
刘素荣a，权 阳a，朱 娇a，刘 娟a，刘静静a，刘 艳b
（兵器工业五二一医院 a. 肿瘤内科；b. 检验科，西安 710065）
Author(s):
LIU Suronga，QUAN Yanga，ZHU Jiaoa，LIU Juana，LIU Jingjinga，LIU Yanb
（a.Department of Medical Oncology； b. Department of Clinical Laboratory，Ordnance Industry 521 Hospital，Xi’an 710065，China)
关键词:
非小细胞肺癌; 核转运蛋白β1; Mer 受体酪氨酸激酶; 无进展生存
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.01.010
文献标志码:
A
摘要:
目的 研究非小细胞肺癌(NSCLC) 组织中核转运蛋白β1(KPNB1)、Mer 受体酪氨酸激酶(MERTK) 的表达水平与临床病理特征的相关性及无进展生存预后的研究。方法 选取2018 年2 月～ 2020 年2 月在兵器工业五二一医院就诊的118 例NSCLC 患者。采用免疫组织化学法（IHC）检测NSCLC 癌组织和癌旁组织中KPNB1，MERTK 的表达。使用Kaplan-Meier 法评估KPNB1，MERTK 表达与患者无进展生存的关系；COX 回归分析影响患者无进展生存的因素。结果 癌组织KPNB1（61.02%），MERTK（62.71%）阳性率高于癌旁组织（8.48%，6.78%），差异具有统计学意义(χ2=69.945，81.408，均P ＜ 0.001)。癌组织中KPNB1 与MERTK 表达呈显著正相关（r=0.744，P ＜ 0.001）。淋巴结转移、TNM 分期Ⅲ A 期NSCLC 癌组织KPNB1（84.21%，82.50%），MERTK（84.21%，85.00%）阳性率高于无淋巴结转移（50.00%，52.50%），TNM 分期Ⅰ～Ⅱ期（50.00%，51.28%），差异具有统计学意义(χ2=11.078 ～ 12.855，均P ＜ 0.001)。KPNB1 和MERTK 阳性、阴性组三年无进展生存率分别为26.39%（19/72）和56.52%（26/46），27.03%（20/74）和56.82%（25/44），差异具有统计学意义（Log-Rank χ2=10.980，8.463，P=0.001，0.004）。KPNB1 阳性、MERTK 阳性、淋巴结转移、TNM 分期Ⅲ A 期是NSCLC 患者无进展生存预后的危险因素（waldχ2=7.810 ～ 10.906，均P ＜ 0.001）。结论 NSCLC 中KPNB1，MERTK 表达升高，两者与TNM 分期及淋巴结转移有关，是新的评估NSCLC 无进展生存预后的标志物。
Abstract:
Objective To study the expression levels of karyopherin β1(KPNB1) and Mer receptor tyrosine kinase (MERTK) in non-small cell lung cancer (NSCLC) tissues and their correlation with clinical pathological features, as well as the prognosis of progression-free survival. Methods A total of 118 NSCLC patients who visited Ordnance Industry 521 Hospital from February 2018 to February 2020 were selected. Immunohistochemical methods were used to detect the expression of KPNB1 and MERTK in NSCLC cancer and paracancer tissue. Kaplan-Meier survival curve analysis was conducted to assess the impact of KPNB1 and MERTK on the progression-free survival prognosis of NSCLC patients. COX regression analysis was performed to identify factors affecting the prognosis of progression-free survival in NSCLC patients. Results The positive rates of KPNB1 (61.02%) and MERTK (62.71%) in cancer tissues were higher than those in adjacent tissues (8.48%, 6.78%), and the differences were statistically significant (χ2=69.945，81.408，all P<0.001). There was a significant positive correlation between KPNB1 and MERTK expression in the organization (r=0.744, P ＜ 0.001). The positive rates of KPNB1（84.21%，82.50%），MERTK （84.21%，85.00%）in NSCLC tissues with lymph node metastasis and TNM stage Ⅲ A were higher than those without lymph node metastasis（50.00%，52.50%） and TNM stage Ⅰ ~ Ⅱ（50.00%，51.28%）, and the differences were statistically significant (χ2=11.078 ～ 12.855，all P<0.001). The 3-year progression-free survival rates of KPNB1and MERTK positive and negative groups were 26.39% (19/72) and 56.52% (26/46), 27.03% (20/74) and 56.82% (25/44), respectively, with statistically significant differences (Log Rankχ2=0.980, 8.463, P=0.001, 0.004) . KPNB1 positive，MERTK positive, lymph node metastasis and TNM stage Ⅲ A were risk factors for progression free survival prognosis in NSCLC patients (waldχ2=7.810 ～ 10.906 , all P ＜ 0.001). Conclusion The expression of KPNB1 and MERTK is elevated in NSCLC, both of which are related to TNM staging and lymph node metastasis. They are new biomarkers for evaluating the progression-free survival prognosis of NSCLC.

参考文献/References:

[1] BADE B C, DELA CRUZ C S. Lung cancer 2020: epidemiology, etiology, and prevention[J]. Clinics in Chest Medicine, 2020, 41(1): 1-24.
[2] 刘捷，杨玲玲，程秋霞，等．非小细胞肺癌患者血清miR-873 和miR-138-5p 表达水平及其与免疫微环境及预后的相关性分析[J]．现代检验医学杂志，2024，39（1）：23-28． LIU Jie, YANG Lingling, CHENG Qiuxia, et al. Analysis of the relationship between serum miR-873 and miR-138-5p expression and immune microenvironment and prognosis in patients with nonsmall cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2024, 39(1): 23-28.
[3] KHALIL B, CHHANGANI D, WREN M C, et al. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy[J]. Molecular neurodegeneration, 2022, 17(1): 80.
[4] SHI Qiwen, LIN Mengxia, CHENG Xiang, et al. KPNB1-mediated nuclear import in cancer [J]. European Journal of Pharmacology, 2023, 955: 175925.
[5] KELENIS D P, RODARTE K E, KOLLIPARA R K, et al. Inhibition of karyopherin β1-mediated nuclear import disrupts oncogenic lineage-defining transcription factor activity in small cell lung cancer[J]. Cancer Research, 2022, 82(17): 3058-3073.
[6] POLI F E, YUSUF I H, CLOUSTON P, et al. MERTK missense variants in three patients with retinitis pigmentosa[J]. Ophthalmic Genetics, 2023, 44(1): 74-82.
[7] LAHEY K C, GADIYAR V, HILL A, et al. Mertk: an emerging target in cancer biology and immunooncology [J]. International Review of Cell and Molecular Biology, 2022, 368: 35-59.
[8] BATRA U, MUNSHI A, KABRA V, et al. Relevance of multi-disciplinary team approach in diagnosis and management of Stage III NSCLC[J]. Indian Journal of Cancer, 2022, 59(Supplement): S46-S55.
[9] SHE Yunlang, JIN Zhuochen, WU Junqi, et al. Development and validation of a deep learning model for non-small cell lung cancer survival[J]. JAMA Network Open, 2020, 3(6): e205842.
[10] YANG Jian, GUO Yuqi, LU Cuijie, et al. Inhibition of karyopherin beta 1 suppresses prostate cancer growth[J]. Oncogene, 2019, 38(24): 4700-4714.
[11] YANG Fan, LI Lin, MU Zhenzhen, et al. Tumorpromoting properties of karyopherin β1 in melanoma by stabilizing Ras-GTPase-activating protein SH3 domain-binding protein 1[J].Cancer Gene Therapy, 2022, 29(12): 1939-1950.
[12] WANG Haiying, WANG Danping, LI Chunsun, et al. High Kpnβ1 expression promotes non-small cell lung cancer proliferation and chemoresistance via the PI3-kinase/AKT pathway [J]. Tissue & Cell, 2018,51:39-48.
[13] CAO Yiqiang, WANG Fei, CHEN Yu, et al. CircPITX1 regulates proliferation, angiogenesis, migration, invasion, and cell cycle of human glioblastoma cells by targeting miR-584-5p/KPNB1 axis[J]. Journal of Molecular Neuroscience, 2021, 71(8): 1683-1695.
[14] LI Wei, YANG Pan, ZHONG Chucheng, et al. The circ-PITX1 promotes non-small cell lung cancer development via the miR-30e-5p/ITGA6 axis[J]. Cell Cycle, 2022, 21(3): 304-321.
[15] DU Wenwen, ZHU Jianjie, ZENG Yuanyuan, et al. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway[J]. Cell Death and Differentiation, 2021, 28(4): 1284-1300.
[16] NEWELL S, VAN DER WATT P J, LEANER V D. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy[J]. IUBMB Life, 2024, 76(1): 4-25.
[17] DAVRA V, KUMAR S, GENG Ke, et al. Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity[J]. Cancer Research, 2021, 81(3): 698-712.
[18] YAN Dan, HUELSE J, PARKER R, et al. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer [J].the Journal Clinical Investigation, 2022, 132(15):e150517.
[19] LIU Yongzhang,LAN Linhua,LI Yujie, e t al . N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth [J]. Redox Biology, 2022, 54: 102366.
[20] CHEN Chaoju, LIU Yupeng. MERTK inhibition: potential as a treatment strategy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer[J]. Pharmaceuticals (Basel, Switzerland), 2021, 14(2): 130.
[21] YAN Dan. Hope and challenges: immunotherapy in EGFR-mutant NSCLC patients [J]. Biomedicines, 2023, 11(11): 2916.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(01):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(01):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华,齐宗利,张海祥,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Hua,QI Zong-li,ZHANG Hai-xiang,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(01):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：陕西省科学技术厅科技计划(2021SF-127)。
作者简介：刘素荣（1981-），女，硕士，副主任医师，研究方向：肺癌，E-mail：Liu1234su@163.com。
通讯作者：权阳，E-mial：1679642419@qq.com。
更新日期/Last Update: 2025-01-15